Sulfasalazine is metabolized by intestinal bacteria, resulting in the release of sulfapyridine
and 5-aminosalicylate. The drug is useful in the treatment of active ulcerative colitis as well as …

Inflammatory bowel disease (IBD) is comprised of Crohn’s disease and ulcerative colitis,
both chronic inflammatory intestinal disorders of unknown etiology characterized by a waxing …

Background & Aims: We assessed the relationship between antibodies to infliximab (ATI)
and the loss of response postinfliximab, infusion reactions and, in a randomized trial, …

Background and Aims: Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease.
We aimed to assess whether clinical, biological, and histologic parameters in quiescent …

When salicylazosulfapyridine (SAS) is fed to conventional rats, none of the drug is re
covered in the urine, feces or cecum; the excreta contain tile products of azo bond re duction, …

Background & Aims: No therapy has been shown to reliably prevent the evolution of
postoperative recurrence of Crohn’s disease. The aim of the current trial was to compare 6-…

… S Garud and MA Peppercorn … S Garud and MA Peppercorn … Conflict of interest statement
Dr Peppercorn is on the Speaker bureau for Procter and Gamble and Abbott Pharmaceuticals. …

… Twenty micrograms of RNA were electropheresed for 4 hr at 60 V (80 mA) and then
transferred to Hybond N+ nylon filters according to the recommendations of Amersham. After air …

Background: Mesalamine is released from sulfasalazine in the colon and benefits colonic
Crohn's disease. The mesalamine used in this study releases the drug throughout the small …

OBJECTIVES: To determine the association between psychosocial characteristics and time
to relapse in patients with inactive ulcerative colitis. METHODS: Sixty patients with clinically …